Literature DB >> 7720390

Contact allergy to kojic acid in skin care products.

M Nakagawa1, K Kawai, K Kawai.   

Abstract

Kojic acid (5-hydroxy-2-(hydroxymethyl)-4-pyrone), a fungal metabolic product, has increasingly been used as a skin-depigmenting agent in skin care products marketed in Japan since 1988. In order to determine its frequency of sensitization, during 1 year from October 1992 to September 1993, we performed patch testing with it in 220 female patients with suspected cosmetic-related contact dermatitis. Of the 220 patients, 8 used at least 1 skin care product containing kojic acid, 5 of whom reacted to kojic acid as well as to 1 or more their own products containing 1% kojic acid, but not to their other products not containing it, and 3 of whom were negative to kojic acid and all their own products. Patch testing with kojic acid in the remaining group of 212 patients, who had not previously used skin care products containing it, was negative without exception. The 5 kojic-acid-sensitive patients, aged 34 to 58 years, developed facial dermatitis 1-12 months after starting application of kojic-acid-containing products. Kojic acid is considered to have high sensitizing potential, as a comparatively high frequency of contact sensitivity was observed in patients using products containing it (5 out of 8).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7720390     DOI: 10.1111/j.1600-0536.1995.tb00832.x

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN: 0105-1873            Impact factor:   6.600


  26 in total

1.  Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color.

Authors:  Erica C Davis; Valerie D Callender
Journal:  J Clin Aesthet Dermatol       Date:  2010-07

2.  [Methods and means for pigmentation and depigmentation. Sense or nonsense?].

Authors:  V Hegyi; J Hegyi
Journal:  Hautarzt       Date:  2010-07       Impact factor: 0.751

Review 3.  Dermatology: how to manage facial hyperpigmentation in skin of colour.

Authors:  Siddiq Moolla; Yvette Miller-Monthrope
Journal:  Drugs Context       Date:  2022-05-31

4.  Lyoniresinol inhibits melanogenic activity through the induction of microphthalmia-associated transcription factor and extracellular receptor kinase activation.

Authors:  Huiyu Liu; Xiaoxin Sui; Xiaohong Li; Yuzhen Li
Journal:  Mol Cell Biochem       Date:  2012-10-26       Impact factor: 3.396

5.  Modifying skin pigmentation - approaches through intrinsic biochemistry and exogenous agents.

Authors:  Michaela Brenner; Vincent J Hearing
Journal:  Drug Discov Today Dis Mech       Date:  2008

6.  Adverse cutaneous reactions to skin care products on the face vary with age, but not with sex.

Authors:  Li-Ning Huang; Yi-Ping Zhong; Dan Liu; Xiao-Hua Wang; Can-Yi Gong; Si Wen; Peter M Elias; Bin Yang; Mao-Qiang Man
Journal:  Contact Dermatitis       Date:  2018-09-12       Impact factor: 6.600

7.  Topical treatment of melasma.

Authors:  Debabrata Bandyopadhyay
Journal:  Indian J Dermatol       Date:  2009       Impact factor: 1.494

8.  Kojic Acid vis-a-vis its Combinations with Hydroquinone and Betamethasone Valerate in Melasma: A Randomized, Single Blind, Comparative Study of Efficacy and Safety.

Authors:  Kirti S Deo; Kedar N Dash; Yugal K Sharma; Neha C Virmani; Chetan Oberai
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

9.  Ssanghwa-tang, an oriental herbal cocktail, exerts anti-melanogenic activity by suppression of the p38 MAPK and PKA signaling pathways in B16F10 cells.

Authors:  Aeyung Kim; Nam-Hui Yim; Minju Im; Young Pil Jung; Chun Liang; Won-Kyung Cho; Jin Yeul Ma
Journal:  BMC Complement Altern Med       Date:  2013-08-28       Impact factor: 3.659

10.  Activation of MITF by Argan Oil Leads to the Inhibition of the Tyrosinase and Dopachrome Tautomerase Expressions in B16 Murine Melanoma Cells.

Authors:  Myra O Villareal; Sayuri Kume; Thouria Bourhim; Fatima Zahra Bakhtaoui; Kenichi Kashiwagi; Junkyu Han; Chemseddoha Gadhi; Hiroko Isoda
Journal:  Evid Based Complement Alternat Med       Date:  2013-07-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.